What Your CEO is Reading: New GLP‑1 Most Favored Nation Pricing Deal Raises Questions for Employers

The Trump administration announced a “Most Favored Nation” agreement which includes caps on costs for GLP-1 injectables and forthcoming oral formulations for public payors and direct-to-consumer platforms – with the role of employer plans still unclear.